Market cap, ratios, CAGR and revenue: company table snapshot as of 6 Nov 2026 (the same figures on every page). Price: snapshot as of 6 Nov 2026. Not investment advice.
Where it fits
Makes and services the capital equipment (CT, MRI, cath labs, ventilators, robots) and implants (stents, heart valves, joints, dental crowns and aligners) that hospitals buy. Global majors (Siemens Healthineers, GE HealthCare, Philips, Medtronic) dominate high-end equipment, with Indian makers growing in implants, disposables and mid-range devices.
Why it matters
Every new bed needs equipment: the chains' bed-addition wave is a multi-year order book for medtech. India still imports most of its high-end devices, so local makers that clear quality approvals (CDSCO, CE, USFDA) gain from policy support and from hospitals' search for cheaper suppliers.
Where the value pool sits
Implant and device makers earn 20-30% EBITDA margins when they have scale and approvals; equipment service contracts add recurring revenue. Prices of coronary stents and knee implants have been capped by NPPA since 2017, which limits pricing in those categories.
Key drivers
Hospital bed additions and equipment upgrades
PLI for medical devices and the national medical devices policy (aim: cut import dependence)
Exports by Indian makers to Europe, the US and emerging markets
Potential bottlenecks
Import dependence for high-end imaging and electronics
Long regulatory approvals and clinical evidence requirements
NPPA price caps on stents and knee implants
Investor metrics to watch
Export share and number of regulated-market approvals
Capacity additions and utilisation
Share of new high-value products (cardiology, renal, ortho)